2-(3-Methylphenyl)pent-3-yn-2-ol | 96307-86-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(3-Methylphenyl)pent-3-yn-2-ol
• CAS: 96307-86-7
• 化学式: C₁₂H₁₄O
• 分子量: 174.243
• InChiKey: UTMMOOUBPHLOGP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-(3-Methylphenyl)pent-3-yn-2-ol 在 五氟化锑 、 氟磺酸 作用下， 以 various solvent(s) 为溶剂， 生成 1-methyl-3-pent-3-yn-2-ylbenzene
  参考文献：
  名称：

  Considered stable cations. 259. Application of the Gassman-Fentiman tool of increasing electron demand to the carbon-13 NMR spectroscopic study of 1-aryl-3-methylbut-2-enyl (allylic) and 2-arylpent-3-yn-2-yl (propargylic) cations

  摘要：

  DOI：

  10.1021/ja00299a030
• 作为产物：
  描述：

  丙基锂 、 3'-甲基苯乙酮 以 四氢呋喃 为溶剂， 生成 2-(3-Methylphenyl)pent-3-yn-2-ol
  参考文献：
  名称：

  Considered stable cations. 259. Application of the Gassman-Fentiman tool of increasing electron demand to the carbon-13 NMR spectroscopic study of 1-aryl-3-methylbut-2-enyl (allylic) and 2-arylpent-3-yn-2-yl (propargylic) cations

  摘要：

  DOI：

  10.1021/ja00299a030

文献信息

• [EN] THERAPEUTIC COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS THÉRAPEUTIQUES ET LEURS UTILISATIONS
  申请人：GENENTECH INC

  公开号：WO2016123391A1

  公开（公告）日：2016-08-04

  The present invention relates to compounds of formula (I): and to salts thereof, wherein R1-R6 have any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of TAF1. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various TAF1-mediated disorders.

  本发明涉及式(I)的化合物及其盐，其中R1-R6具有规范中定义的任何值，以及其组合物和用途。这些化合物可用作TAF1的抑制剂。还包括包含式(I)的化合物或其药学上可接受的盐的药物组合物，以及在治疗各种TAF1介导的疾病中使用这些化合物和盐的方法。
• Therapeutic compounds and uses thereof
  申请人：GENENTECH, INC.

  公开号：US10202378B2

  公开（公告）日：2019-02-12

  The present invention relates to compounds of formula (I): and to salts thereof, wherein R1-R6 have any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of TAF1. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various TAF1-mediated disorders.

  本发明涉及式（I）化合物： 及其盐，其中 R1-R6 具有说明书中定义的任一值，以及其组合物和用途。这些化合物可用作 TAF1 的抑制剂。还包括包含式（I）化合物或其药学上可接受的盐的药物组合物，以及使用此类化合物和盐治疗各种TAF1介导的疾病的方法。
• THERAPEUTIC COMPOUNDS AND USES THEREOF
  申请人：GENENTECH, INC.

  公开号：US20180009805A1

  公开（公告）日：2018-01-11

  The present invention relates to compounds of formula (I): and to salts thereof, wherein R 1 -R 6 have any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of TAF1. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various TAF1-mediated disorders.
• Considered stable cations. 259. Application of the Gassman-Fentiman tool of increasing electron demand to the carbon-13 NMR spectroscopic study of 1-aryl-3-methylbut-2-enyl (allylic) and 2-arylpent-3-yn-2-yl (propargylic) cations
  作者：G. K. Surya Prakash、V. V. Krishnamurthy、George A. Olah、D. G. Farnum

  DOI：10.1021/ja00299a030

  日期：1985.6